Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Follicular Lymphoma
Interventions
DRUG

rituximab

375 mg/m² IV, D1 each cycle during 4 cycles

DRUG

fludarabine

40 mg/m²/day IV , D1 each cycle during 4 cycles

DRUG

mitoxantrone

10 mg/m² IV, D2-3-4 each cycle during 4 cycles

Trial Locations (16)

13273

Service d'hématologie Institut Paoli Calmette, Marseille

25030

Service d'Hématologie Hôpital Jean Minjoz, Besançon

35033

Service d'hématologie clinique - Hôpital de Pontchaillou, Rennes

37044

Service Oncologie CHU Bretonneau, Tours

38043

Hôpital A. Michallon BP 217X, Grenoble

49033

Service de médecine D - Maladies du Sang CHU Angers, Angers

59037

Hôpital Claude Huriez - Sce des Maladies du Sang - Place Verdun, Lille

62307

Service d'hématologie clinique - Centre Hospitalier du Dr Schaffner, Lens

69310

Centre Hospitalier Lyon-sud, Lyon

69373

Centre régional de lutte contre le cancer Léon Bérard, Lyon

72015

Service Oncologie - Centre Victor Hugo, Le Mans

75015

Service d'hématologie - Hôpital Necker, Paris

75475

Service d'Hématologie Hôpital St Louis, Paris

76038

Centre Henri Becquerel, Rouen

94010

Hôpital Henri Mondor, Créteil

94805

Service d'hématologie Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Lymphoma Study Association

OTHER

NCT00169208 - Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter